| 尚卿，王海鹏.超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌疗效及病灶无进展生存时间分析[J].实用中西医结合临床,2023,23(16):6-10 |
| 超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌疗效及病灶无进展生存时间分析 |
| Clinical Outcomes and Progression-Free-Survival Time of Patients with Stage Ⅲ~Ⅳ Primary Liver Cancer Receiving Ultrasound-Guided Percutaneous Microwave Ablation |
| |
| DOI： |
| 中文关键词: 原发性肝癌 Ⅲ~Ⅳ期 超声引导下微波介入 病灶无进展 生存时间 |
| 英文关键词: Primary liver cancer Stage Ⅲ~Ⅳ Ultrasound-guided percutaneous microwave ablation Efficacy Progression-free-survival |
| 基金项目: |
|
| 摘要点击次数: 125 |
| 全文下载次数: 96 |
| 中文摘要: |
| 目的：分析超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌（PLC）疗效及病灶无进展生存时间。方法：随机选择医院2020年8月至2021年8月诊治的122例Ⅲ~Ⅳ期PLC患者，根据入院顺序不同分为对照组60例和观察组62例。对照组接受经肝动脉的化疗栓塞相关治疗，观察组实施超声引导下微波介入治疗。比较两组血清肿瘤标志物水平、临床疗效、病灶无进展生存时间、生活质量、并发症及不良反应。结果：治疗后，两组癌胚抗原（CEA）、甲胎蛋白（AFP）水平较治疗前下降，且观察组低于对照组（P＜0.05）；两组治疗后天冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、γ-谷氨酰转肽酶（GGT）、碱性磷酸酯酶（ALP）和总胆红素（TBil）均低于治疗前，直接胆红素（DBil）高于治疗前，差异有统计学意义（P＜0.05），但两组治疗后数据对比，差异无统计学意义（P＞0.05）；两组治疗后视觉模拟法评分（VAS）较治疗前下降，且观察组低于对照组（P＜0.05）；观察组完全缓解率高于对照组（P＜0.05），局部残留率和转移复发率低于对照组（P＜0.05）；观察组病灶无进展生存时间长于对照组（P＜0.05）；两组治疗后生活质量评分上升，且观察组高于对照组（P＜0.05）；观察组并发症发生率低于对照组（P＜0.05），不良反应发生率低于对照组（P＜0.05）。结论：超声引导下微波介入治疗Ⅲ~Ⅳ期PLC能明显提升疗效，延长病灶无进展生存时间，改善其日常的生活质量。 |
| 英文摘要: |
| Objective: To analyze the efficacy and progression-free survival time of ultrasound-guided microwave interventional therapy for stage Ⅲ~Ⅳ primary liver cancer (PLC). Methods: A total of 122 patients with PLC in the hospital from August 2020 to August 2021 were randomly selected and divided into control group (60 cases) and observation group (62 cases) according to different admission sequence. Control group received transhepatic arterial chemotherapeutic embolism, and observation group received ultrasound-guided percutaneous microwave ablation. Serum tumor marker levels, clinical efficacy, progression-free survival time, quality of life, complications and adverse reactions were compared between the two groups. Results: After treatment, the levels of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in two groups were lower than before treatment, and the observation group was lower than the control group (P＜0.05). After treatment, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin (TBil) were lower than before treatment, and direct bilirubin (DBil) was higher than before treatment, the difference was statistically significant (P＜0.05). However, there was no significant difference between the two groups after treatment (P＞0.05). The visual analogue score (VAS) of the two groups after treatment was lower than that before treatment, and the observation group was lower than the control group (P＜0.05). The complete remission rate of observation group was higher than that of control group (P＜0.05), and the local residual rate and recurrence rate of metastasis were lower than that of control group (P＜0.05). The progression-free-survival time of observation group was longer than that of control group (P＜0.05). The quality of life score of the two groups increased after treatment, and the observation group was higher than the control group (P＜0.05). The incidence of complications and adverse reactions in the observation group was lower than that in the control group (P＜0.05). Conclusion: Ultrasound-guided percutaneous microwave ablation for stage Ⅲ~Ⅳ PLC can significantly improve the curative effect, prolong the progression-free survival time, and improve the daily quality of life. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
